Publications by authors named "M N Hilleret"
Background And Aims: Bulevirtide (BLV) 2 mg/day is EMA approved for treatment of compensated chronic hepatitis due to Delta virus (HDV) infection, however real-life data in large cohorts of patients with cirrhosis are lacking.
Methods: Consecutive HDV-infected patients with cirrhosis starting BLV 2 mg/day since September 2019 were included in a European retrospective multicenter real-life study (SAVE-D). Patient characteristics before and during BLV treatment were collected.
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfection.
Methods: Patients received BLV 2 mg ± pegylated interferon-α (pegIFNα) according to the physician's decision.
Article Synopsis
- A phase 2b trial tested the effectiveness of bulevirtide combined with peginterferon alfa-2a compared to peginterferon alone and bulevirtide alone in treating chronic hepatitis D over 48 weeks, with follow-up for an additional 48 weeks.* -
- Results showed that 46% of patients receiving the 10 mg bulevirtide and peginterferon had undetectable levels of the hepatitis D virus 24 weeks after treatment, compared to only 17% in the peginterferon alone group.* -
- The combination therapy indicated a statistically significant improvement in viral response, suggesting that bulevirtide and peginterferon could be a beneficial treatment strategy
Background: Partial splenic embolization (PSE) has been proposed to treat the consequences of hypersplenism in the context of portal hypertension, especially thrombocytopenia. However, a high morbidity/mortality rate has made this technique unpopular. We conducted a multicenter retrospective nationwide French study to reevaluate efficacy and tolerance.
View Article and Find Full Text PDFBackground And Aims: Since the introduction of SARS-CoV-2 vaccines, several cases of vaccine-induced immune thrombocytopenia and thrombosis (VITT) have been described, especially cerebral vein thrombosis. We aimed to retrospectively collect all new cases of acute onset first or recurrent splanchnic vein thrombosis (SVT) following a recent SARS-CoV-2 vaccination within the Vascular Liver Disease Group network.
Approach And Results: New cases of SVT were identified from April 2021 to April 2022; follow-up was completed on December 31, 2022.